- Article
Real-World Clinical Outcomes Associated with Canagliflozin in Patients Aged 65 Years and Older with Type 2 Diabetes Mellitus in Spain: The Old Real-Wecan Study
- Manuel A. Gargallo-Fernández,
- Alba Galdón Sanz-Pastor,
- Teresa Antón-Bravo,
- Miguel Brito-Sanfiel,
- Jaime Wong-Cruz and
- Juan J. Gorgojo-Martínez
The observational Real-Wecan study showed that canagliflozin 100 mg (CANA100) as an add-on therapy, and canagliflozin 300 (CANA300), switching from prior SGLT-2i therapy, significantly improved several cardiometabolic parameters in patients with T2DM...

